IL156158A0 - Lactam compounds and pharmaceutical use thereof - Google Patents

Lactam compounds and pharmaceutical use thereof

Info

Publication number
IL156158A0
IL156158A0 IL15615801A IL15615801A IL156158A0 IL 156158 A0 IL156158 A0 IL 156158A0 IL 15615801 A IL15615801 A IL 15615801A IL 15615801 A IL15615801 A IL 15615801A IL 156158 A0 IL156158 A0 IL 156158A0
Authority
IL
Israel
Prior art keywords
diabetic
pharmaceutical use
lactam compounds
agent
adiposis
Prior art date
Application number
IL15615801A
Other languages
English (en)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of IL156158A0 publication Critical patent/IL156158A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
IL15615801A 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof IL156158A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (fr) 2000-12-01 2001-11-29 Composes de lactame et leur utilisation medicale

Publications (1)

Publication Number Publication Date
IL156158A0 true IL156158A0 (en) 2003-12-23

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15615801A IL156158A0 (en) 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof

Country Status (26)

Country Link
US (3) US7153850B2 (pt)
EP (1) EP1346993B1 (pt)
JP (2) JP3826400B2 (pt)
KR (1) KR100826818B1 (pt)
CN (2) CN1269818C (pt)
AT (1) ATE446297T1 (pt)
AU (3) AU2002218502B2 (pt)
BG (1) BG107857A (pt)
BR (1) BR0115852A (pt)
CA (1) CA2430124C (pt)
CZ (1) CZ20031520A3 (pt)
DE (1) DE60140270D1 (pt)
ES (1) ES2331299T3 (pt)
HU (1) HUP0400806A3 (pt)
IL (1) IL156158A0 (pt)
MX (1) MXPA03004876A (pt)
NO (1) NO325401B1 (pt)
NZ (1) NZ526164A (pt)
PL (1) PL362835A1 (pt)
RU (1) RU2287530C2 (pt)
SK (1) SK6582003A3 (pt)
TW (1) TWI241302B (pt)
UA (1) UA76969C2 (pt)
WO (1) WO2002044180A1 (pt)
YU (1) YU42603A (pt)
ZA (1) ZA200304100B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115852A (pt) 2000-12-01 2003-12-23 Ajinomoto Kk Composto de lactama ou um seu sal farmaceuticamente aceitável, agente para aumentar a capacidade de transporte de açúcar, agentes hipoglicêmico e para prevenir e/ou tratar diabetes, neuropatia periférica diabética, nefropatia diabética, retinopatia diabética, macroangiopatia diabética, tolerância prejudicada à glicose ou adipose, e, composição farmacêutica
AU2004210268B8 (en) * 2003-02-07 2009-06-04 Ajinomoto Co., Inc. Therapeutic agents for diabetes
WO2005042536A1 (ja) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
WO2005068467A1 (ja) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
WO2006118341A1 (ja) * 2005-04-28 2006-11-09 Ajinomoto Co., Inc. 新規ラクタム化合物
JP5672699B2 (ja) 2007-04-11 2015-02-18 味の素株式会社 血糖降下作用化合物のスクリーニング法
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
KR20170095850A (ko) * 2014-12-22 2017-08-23 이에이 파마 가부시키가이샤 각막 상피 장애 치료제
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
MX2021008937A (es) * 2019-01-23 2021-11-12 Glycolysis Biomed Co Ltd Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
AU8592598A (en) 1997-07-30 1999-02-22 Wyeth Tricyclic vasopressin agonists
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
BR0115852A (pt) 2000-12-01 2003-12-23 Ajinomoto Kk Composto de lactama ou um seu sal farmaceuticamente aceitável, agente para aumentar a capacidade de transporte de açúcar, agentes hipoglicêmico e para prevenir e/ou tratar diabetes, neuropatia periférica diabética, nefropatia diabética, retinopatia diabética, macroangiopatia diabética, tolerância prejudicada à glicose ou adipose, e, composição farmacêutica
AU2004210268B8 (en) 2003-02-07 2009-06-04 Ajinomoto Co., Inc. Therapeutic agents for diabetes

Also Published As

Publication number Publication date
AU1850202A (en) 2002-06-11
JP3826400B2 (ja) 2006-09-27
JP4505753B2 (ja) 2010-07-21
US7153850B2 (en) 2006-12-26
US20080096862A1 (en) 2008-04-24
RU2287530C2 (ru) 2006-11-20
AU2002218502B2 (en) 2006-09-21
US20040048847A1 (en) 2004-03-11
ZA200304100B (en) 2004-08-22
HUP0400806A3 (en) 2007-11-28
CN1487940A (zh) 2004-04-07
UA76969C2 (en) 2006-10-16
BR0115852A (pt) 2003-12-23
PL362835A1 (en) 2004-11-02
AU2006241377A1 (en) 2006-12-14
ATE446297T1 (de) 2009-11-15
NO325401B1 (no) 2008-04-21
JPWO2002044180A1 (ja) 2004-04-02
AU2006241377B2 (en) 2009-01-08
WO2002044180A1 (fr) 2002-06-06
KR100826818B1 (ko) 2008-05-02
JP2006213732A (ja) 2006-08-17
NO20032439L (no) 2003-07-18
DE60140270D1 (de) 2009-12-03
EP1346993A4 (en) 2005-12-21
CN1269818C (zh) 2006-08-16
YU42603A (sh) 2006-03-03
CN1911915A (zh) 2007-02-14
CZ20031520A3 (cs) 2003-10-15
CA2430124A1 (en) 2002-06-06
CN100577651C (zh) 2010-01-06
US7326701B2 (en) 2008-02-05
TWI241302B (en) 2005-10-11
EP1346993A1 (en) 2003-09-24
SK6582003A3 (en) 2003-09-11
CA2430124C (en) 2011-01-11
BG107857A (bg) 2004-06-30
EP1346993B1 (en) 2009-10-21
MXPA03004876A (es) 2004-01-27
US20060189597A1 (en) 2006-08-24
KR20030051893A (ko) 2003-06-25
US7632830B2 (en) 2009-12-15
NO20032439D0 (no) 2003-05-28
HUP0400806A2 (hu) 2004-07-28
ES2331299T3 (es) 2009-12-29
NZ526164A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
IL156158A0 (en) Lactam compounds and pharmaceutical use thereof
MXPA03007712A (es) Sales farmaceuticas.
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
CA2386690A1 (en) Pharmaceutical tramadol salts
EP1308168A4 (en) NEW MEDICINES FOR CANCER
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
HK1046501A1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient.
SI1197223T1 (pt)
ZA200304928B (en) Medicament containing a polyamine as an active substance.
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
EP0953355A4 (en) MEDICINE FOR AUTOIMMUNE DISEASES
WO2003011247A3 (de) Trägermatrix mit wirkstoffbeladenen partikeln zur anwendung auf der haut oder schleimhaut
TW200509980A (en) Parasiticidal composition
EP1062948A4 (en) MEDICINAL PRODUCTS FOR DIASTOLIC HEART DISEASES
WO2001060398A8 (fr) Medicaments destines a ameliorer l'intolerance au glucose
EP1234834A4 (en) 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT
ZA200202426B (en) Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient.
WO2001037818A3 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
WO2002024210A3 (en) Halogen compounds for use in medicine
AU2001241067A1 (en) Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient